Transmembrane Protease, serine 2 (TMPRSS2) antibody

Antigen: Transmembrane Protease, serine 2 (TMPRSS2)

Clonality: Monoclonal

Host: Rabbit

Reactivity: Human, Rat (Rattus)

Conjugate: Un-conjugated

Application: Western Blotting (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC), Flow Cytometry (FACS)

Certificates: ISO 9001:2008

Catalog no.: ABIN650540

Additional Information

Alternative name: TMPRSS2

Gene ID: 5905

UniProt: O15393

Immunogen: A synthetic peptide corresponding to residues in human TMPRSS2 was used as an immunogen.

Characteristics: Rabbit Monoclonal Antibody

Specificity: A synthetic peptide corresponding to residues in human TMPRSS2 was used as an immunogen.

Molecular Weight: 54 kDA

Comments:

Background: Transmembrane protease, serine 2 (TMPRSS2) is a type-II transmembrane serine protease. It encodes a type II trans-membrane domain, a receptor class A domain, a scavenger receptor cysteine-rich domain and a protease domain. The biological function of TMPRSS2 is unknown, however, seine proteases are known to be involved in many physiological and pathological processes (1). TMPRSS2 is expressed highly in primary and metastatic prostate cancers. It is also regulated by androgens and is associated with tumor cell differentiation (1, 2), making it a potential target for cancer therapy and diagnosis. TMPRSS2-ERG fusion, which occurs on account of translocations and interstitial deletions, is implicated in aggressive forms of prostate cancer (3, 4).

Application Details

Application Notes: The suggested dilution is: WB: ~~ 1:5000~10000 IP: ~~ 1:50 ICC: ~~ 1:250~1000 IHC: ~~ 1:1000

Buffer: 50 mM Tris-Glycine (pH 7.4), 0.15 M NaCl, 40% Glycerol, 0.01% sodium azide and 0.05% BSA.

Storage: TMPRSS2 Antibody can be stored at -20°C for up to 12 months from time of receipt.

Research Area: Phospho-specific antibodies, Cell Signaling, Protein Modifications, Cell Structure

Restrictions: For Research Use only

Publications

Product: Korelitz, Sommers: "Responses to drug therapy in ulcerative colitis. Evaluation by rectal biopsy and histopathological changes." in: The American journal of gastroenterology, Vol. 64, Issue 5, pp. 365-70, 1976 (PubMed).

Hermans, van Marion, van Dekken et al.: "TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer." in: Cancer research, Vol. 66, Issue 22, pp. 10658-63, 2006 (PubMed).

Pruitt, Tatusova, Maglott: "NCBI reference sequences (RefSeq): a curated non-redundant sequence database of genomes, transcripts and proteins." in: Nucleic acids research, Vol. 35, Issue Database issue, pp. D61-5, 2007 (PubMed).

Lucas, True, Hawley et al.: "The androgen-regulated type II serine protease TMPRSS2 is differentially expressed and mislocalized in prostate adenocarcinoma." in: The Journal of pathology, Vol. 215, Issue 2, pp. 118-25, 2008 (PubMed).

FitzGerald, Agalliu, Johnson et al.: "Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer." in: BMC cancer, Vol. 8, pp. 230, 2008 (PubMed).